Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.

Buonerba C, Iaccarino S, Dolce P, Pagliuca M, Izzo M, Scafuri L, Costabile F, Riccio V, Ribera D, Mucci B, Carrano S, Picozzi F, Bosso D, Formisano L, Bianco R, De Placido S, Di Lorenzo G.

Cancers (Basel). 2019 Aug 28;11(9). pii: E1259. doi: 10.3390/cancers11091259. Review.

2.

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.

Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-0138. [Epub ahead of print]

PMID:
31371343
3.

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.

Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratù AC, Cascetta P, De Placido P, De Placido S, Bianco R.

Cancers (Basel). 2019 Jul 13;11(7). pii: E981. doi: 10.3390/cancers11070981.

4.

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.

Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL.

Nat Commun. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2.

5.

Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.

Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1433. doi: 10.1158/1078-0432.CCR-18-4268. No abstract available.

PMID:
30770492
6.

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. No abstract available.

7.

Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):875. doi: 10.1158/0008-5472.CAN-18-4087. No abstract available.

PMID:
30770370
8.

Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):874. doi: 10.1158/0008-5472.CAN-18-4086. No abstract available.

PMID:
30770369
9.

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors.

Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, Arpino G, De Laurentiis M, Puglisi F, De Placido S, Del Mastro L.

Front Oncol. 2018 Dec 12;8:608. doi: 10.3389/fonc.2018.00608. eCollection 2018. Review.

10.

D-Aspartate treatment attenuates myelin damage and stimulates myelin repair.

de Rosa V, Secondo A, Pannaccione A, Ciccone R, Formisano L, Guida N, Crispino R, Fico A, Polishchuk R, D'Aniello A, Annunziato L, Boscia F.

EMBO Mol Med. 2019 Jan;11(1). pii: e9278. doi: 10.15252/emmm.201809278.

11.

Resveratrol treatment reduces the vulnerability of SH-SY5Y cells and cortical neurons overexpressing SOD1-G93A to Thimerosal toxicity through SIRT1/DREAM/PDYN pathway.

Laudati G, Mascolo L, Guida N, Sirabella R, Pizzorusso V, Bruzzaniti S, Serani A, Di Renzo G, Canzoniero LMT, Formisano L.

Neurotoxicology. 2019 Mar;71:6-15. doi: 10.1016/j.neuro.2018.11.009. Epub 2018 Nov 29.

12.

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.

Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE Jr, Lalani AS, Miller VA, Lanman RB, Grishin NV, Arteaga CL.

Clin Cancer Res. 2019 Jan 1;25(1):277-289. doi: 10.1158/1078-0432.CCR-18-1544. Epub 2018 Oct 12.

PMID:
30314968
13.

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.

Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, González Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL.

Clin Cancer Res. 2019 Jan 15;25(2):771-783. doi: 10.1158/1078-0432.CCR-18-1131. Epub 2018 Oct 1.

14.

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.

Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM.

Oncoimmunology. 2018 Mar 6;7(6):e1438106. doi: 10.1080/2162402X.2018.1438106. eCollection 2018.

15.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1431.

16.

The miR206-JunD Circuit Mediates the Neurotoxic Effect of Methylmercury in Cortical Neurons.

Guida N, Valsecchi V, Laudati G, Serani A, Mascolo L, Molinaro P, Montuori P, Di Renzo G, Canzoniero LM, Formisano L.

Toxicol Sci. 2018 Jun 1;163(2):569-578. doi: 10.1093/toxsci/kfy051.

PMID:
29522201
17.

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.

Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.

18.

From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.

Formisano L, Jansen VM, Marciano R, Bianco R.

Anticancer Agents Med Chem. 2018;18(9):1235-1240. doi: 10.2174/1871520617666170912123416. Review.

19.

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.

Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, Zambrano N, Fontanini G, Servadio A, Pignataro G, Grumetto L, Lavecchia A, Bruzzese D, Iaccarino A, Troncone G, Veneziani BM, Montuori N, Placido S, Bianco R.

Sci Rep. 2017 Aug 24;7(1):9388. doi: 10.1038/s41598-017-10062-1.

20.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gόmez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaai7993. doi: 10.1126/scitranslmed.aai7993. Erratum in: Sci Transl Med. 2019 Feb 13;11(479):.

21.

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.

Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL.

Clin Cancer Res. 2017 Oct 15;23(20):6138-6150. doi: 10.1158/1078-0432.CCR-17-1232. Epub 2017 Jul 27. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1433.

22.

The neurotoxicant PCB-95 by increasing the neuronal transcriptional repressor REST down-regulates caspase-8 and increases Ripk1, Ripk3 and MLKL expression determining necroptotic neuronal death.

Guida N, Laudati G, Serani A, Mascolo L, Molinaro P, Montuori P, Di Renzo G, Canzoniero LMT, Formisano L.

Biochem Pharmacol. 2017 Oct 15;142:229-241. doi: 10.1016/j.bcp.2017.06.135. Epub 2017 Jul 1.

PMID:
28676433
23.

Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.

Di Mauro C, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Formisano L, De Falco S, Cicatiello V, Di Bonito M, Cantile M, Collina F, Chambery A, Veneziani BM, De Placido S, Bianco R.

Br J Cancer. 2017 May 23;116(11):1425-1435. doi: 10.1038/bjc.2017.116. Epub 2017 Apr 25.

24.

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL.

Cancer Res. 2017 May 1;77(9):2488-2499. doi: 10.1158/0008-5472.CAN-16-2653. Epub 2017 Mar 1. Erratum in: Cancer Res. 2019 Feb 15;79(4):874.

25.

p38/Sp1/Sp4/HDAC4/BDNF Axis Is a Novel Molecular Pathway of the Neurotoxic Effect of the Methylmercury.

Guida N, Laudati G, Mascolo L, Valsecchi V, Sirabella R, Selleri C, Di Renzo G, Canzoniero LM, Formisano L.

Front Neurosci. 2017 Jan 19;11:8. doi: 10.3389/fnins.2017.00008. eCollection 2017.

26.

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.

Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L, Di Mauro C, Orsini RC, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani BM, De Placido S, Bianco R.

Oncotarget. 2016 Jun 28;7(26):40073-40084. doi: 10.18632/oncotarget.9484.

27.

MC1568 Inhibits Thimerosal-Induced Apoptotic Cell Death by Preventing HDAC4 Up-Regulation in Neuronal Cells and in Rat Prefrontal Cortex.

Guida N, Laudati G, Mascolo L, Cuomo O, Anzilotti S, Sirabella R, Santopaolo M, Galgani M, Montuori P, Di Renzo G, Canzoniero LM, Formisano L.

Toxicol Sci. 2016 Dec;154(2):227-240. Epub 2016 Sep 22.

PMID:
27660204
28.

Role of metabolism in neurodegenerative disorders.

Procaccini C, Santopaolo M, Faicchia D, Colamatteo A, Formisano L, de Candia P, Galgani M, De Rosa V, Matarese G.

Metabolism. 2016 Sep;65(9):1376-90. doi: 10.1016/j.metabol.2016.05.018. Epub 2016 Jun 7. Review.

PMID:
27506744
29.

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.

Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL.

Clin Cancer Res. 2017 Jan 1;23(1):26-34. doi: 10.1158/1078-0432.CCR-16-0134. Epub 2016 Apr 28.

30.

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL.

Cancer Res. 2016 Jan 15;76(2):440-52. doi: 10.1158/0008-5472.CAN-15-1640-T. Epub 2015 Dec 16. Erratum in: Cancer Res. 2019 Feb 15;79(4):875.

31.

Methylmercury upregulates RE-1 silencing transcription factor (REST) in SH-SY5Y cells and mouse cerebellum.

Guida N, Laudati G, Anzilotti S, Sirabella R, Cuomo O, Brancaccio P, Santopaolo M, Galgani M, Montuori P, Di Renzo G, Canzoniero LM, Formisano L.

Neurotoxicology. 2016 Jan;52:89-97. doi: 10.1016/j.neuro.2015.11.007. Epub 2015 Nov 21.

PMID:
26610923
32.

Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases.

Conti V, Forte M, Corbi G, Russomanno G, Formisano L, Landolfi A, Izzo V, Filippelli A, Vecchione C, Carrizzo A.

Curr Drug Targets. 2017;18(4):473-484. doi: 10.2174/1389450116666151019095903. Review.

PMID:
26477463
33.

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.

Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R.

Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636.

34.

Resveratrol via sirtuin-1 downregulates RE1-silencing transcription factor (REST) expression preventing PCB-95-induced neuronal cell death.

Guida N, Laudati G, Anzilotti S, Secondo A, Montuori P, Di Renzo G, Canzoniero LM, Formisano L.

Toxicol Appl Pharmacol. 2015 Nov 1;288(3):387-98. doi: 10.1016/j.taap.2015.08.010. Epub 2015 Aug 22.

PMID:
26307266
35.

Mechanisms of lapatinib resistance in HER2-driven breast cancer.

D'Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R.

Cancer Treat Rev. 2015 Dec;41(10):877-83. doi: 10.1016/j.ctrv.2015.08.001. Epub 2015 Aug 8. Review.

PMID:
26276735
36.

Polychlorinated Biphenyls Induce Mitochondrial Dysfunction in SH-SY5Y Neuroblastoma Cells.

Cocco S, Secondo A, Del Viscovo A, Procaccini C, Formisano L, Franco C, Esposito A, Scorziello A, Matarese G, Di Renzo G, Canzoniero LM.

PLoS One. 2015 Jun 23;10(6):e0129481. doi: 10.1371/journal.pone.0129481. eCollection 2015.

37.

Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasion.

Pesapane A, Di Giovanni C, Rossi FW, Alfano D, Formisano L, Ragno P, Selleri C, Montuori N, Lavecchia A.

Oncotarget. 2015 Jul 20;6(20):18116-33.

38.

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.

Troiani T, Napolitano S, Martini G, Martinelli E, Cardone C, Normanno N, Vitagliano D, Morgillo F, Fenizia F, Lambiase M, Formisano L, Bianco R, Ciardiello D, Ciardiello F.

Clin Cancer Res. 2015 Sep 15;21(18):4153-64. doi: 10.1158/1078-0432.CCR-15-0211. Epub 2015 May 27.

39.

Sp3/REST/HDAC1/HDAC2 Complex Represses and Sp1/HIF-1/p300 Complex Activates ncx1 Gene Transcription, in Brain Ischemia and in Ischemic Brain Preconditioning, by Epigenetic Mechanism.

Formisano L, Guida N, Valsecchi V, Cantile M, Cuomo O, Vinciguerra A, Laudati G, Pignataro G, Sirabella R, Di Renzo G, Annunziato L.

J Neurosci. 2015 May 13;35(19):7332-48. doi: 10.1523/JNEUROSCI.2174-14.2015.

40.

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.

Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL.

Mol Cell Proteomics. 2015 Jul;14(7):1959-76. doi: 10.1074/mcp.M115.049783. Epub 2015 May 7.

41.

Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models.

Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, Kim Y, Bastos-Carvalho A, Orlandi A, Ambati J, Ruvo M, Bianco R, De Falco S.

Oncotarget. 2015 Apr 30;6(12):10563-76.

42.

Animal models of Multiple Sclerosis.

Procaccini C, De Rosa V, Pucino V, Formisano L, Matarese G.

Eur J Pharmacol. 2015 Jul 15;759:182-91. doi: 10.1016/j.ejphar.2015.03.042. Epub 2015 Mar 27. Review.

PMID:
25823807
43.

Pentraxin 3 Induces Vascular Endothelial Dysfunction Through a P-selectin/Matrix Metalloproteinase-1 Pathway.

Carrizzo A, Lenzi P, Procaccini C, Damato A, Biagioni F, Ambrosio M, Amodio G, Remondelli P, Del Giudice C, Izzo R, Malovini A, Formisano L, Gigantino V, Madonna M, Puca AA, Trimarco B, Matarese G, Fornai F, Vecchione C.

Circulation. 2015 Apr 28;131(17):1495-505; discussion 1505. doi: 10.1161/CIRCULATIONAHA.114.014822. Epub 2015 Mar 6.

PMID:
25747934
44.

CIKS/DDX3X interaction controls the stability of the Zc3h12a mRNA induced by IL-17.

Somma D, Mastrovito P, Grieco M, Lavorgna A, Pignalosa A, Formisano L, Salzano AM, Scaloni A, Pacifico F, Siebenlist U, Leonardi A.

J Immunol. 2015 Apr 1;194(7):3286-94. doi: 10.4049/jimmunol.1401589. Epub 2015 Feb 20.

45.

Nanoengineered surfaces for focal adhesion guidance trigger mesenchymal stem cell self-organization and tenogenesis.

Iannone M, Ventre M, Formisano L, Casalino L, Patriarca EJ, Netti PA.

Nano Lett. 2015 Mar 11;15(3):1517-25. doi: 10.1021/nl503737k. Epub 2015 Feb 24.

PMID:
25699511
46.

MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.

Formisano L, Guida N, Laudati G, Mascolo L, Di Renzo G, Canzoniero LM.

J Pharmacol Exp Ther. 2015 Feb;352(2):236-43. doi: 10.1124/jpet.114.219345. Epub 2014 Dec 2.

PMID:
25467131
47.

Rac-1 as a new therapeutic target in cerebro- and cardio-vascular diseases.

Carrizzo A, Forte M, Lembo M, Formisano L, Puca AA, Vecchione C.

Curr Drug Targets. 2014;15(13):1231-46. Review.

PMID:
25345393
48.

Extracellular signal-related kinase 2/specificity protein 1/specificity protein 3/repressor element-1 silencing transcription factor pathway is involved in Aroclor 1254-induced toxicity in SH-SY5Y neuronal cells.

Formisano L, Guida N, Laudati G, Boscia F, Esposito A, Secondo A, Di Renzo G, Canzoniero LM.

J Neurosci Res. 2015 Jan;93(1):167-77. doi: 10.1002/jnr.23464. Epub 2014 Aug 5.

PMID:
25093670
49.

Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.

D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti F, Cipolletta A, Bianco C, Ciardiello F, Veneziani BM, De Placido S, Bianco R.

Br J Cancer. 2014 Sep 9;111(6):1168-79. doi: 10.1038/bjc.2014.421. Epub 2014 Aug 5.

50.

Histone deacetylase 4 promotes ubiquitin-dependent proteasomal degradation of Sp3 in SH-SY5Y cells treated with di(2-ethylhexyl)phthalate (DEHP), determining neuronal death.

Guida N, Laudati G, Galgani M, Santopaolo M, Montuori P, Triassi M, Di Renzo G, Canzoniero LM, Formisano L.

Toxicol Appl Pharmacol. 2014 Oct 1;280(1):190-8. doi: 10.1016/j.taap.2014.07.014. Epub 2014 Jul 25.

PMID:
25068794

Supplemental Content

Loading ...
Support Center